<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">The pharmacological approach to treating SARS-CoV-2 infection can be viewed as a 2-phase approach. The first phase is associated with viral replication and cytopathic effect, and antiviral drugs may be considered (e.g., chloroquine-hydroxychloroquine, lopinavir/ritonavir, darunavir ritonavir, and darunavir/cobicistat). The second phase of the disease begins after 7 to 10 days from the onset of symptoms, and is associated with the risk of death
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref>; this stage is characterized by progressive lung involvement with escalating needs of oxygen supplementation and ventilatory support, which seems to be secondary to hyperinflammatory and cytokine release syndromes. Immunosuppressive and immunomodulatory drugs may be of benefit during this phase.
</p>
